Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab

Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab

Shots:

  • Veila Bio to receive $30M upfront licensing fee, additional payment on development and commercial milestones plus royalties on sales of product post-launch
  • MTPC to get exclusive rights to develop and commercialize the product in Japan, South Korea, Taiwan, Singapore, Indonesia, Thailand, Malaysia, the Philippines and Vietnam  
  • Inebilizumab is an anti-CD19 mAb that binds to CD19 with high affinity and is currently under investigation for the treatment of neuromyelitis optica spectrum, disorder (NMOSD)

Click here to­ read full press release/ article | Ref: Mitsubishi Tanabe | Image: Twitter